RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > FDA Approval of Botanical Drugs

FDA Approval of Botanical Drugs

Posted 01 January 2009 | By Max Sherman 

The US Food and Drug Administration (FDA) defines a botanical drug as a product used as a drug that contains as ingredients vegetable materials, which may include plant materials, algae, macroscopic fungi or combinations thereof. Unfortunately, active ingredients found in botanical products are difficult to characterize, as are the methods to measure their potency. Moreover, the composition of vegetable materials can vary from season to season and farm to farm. Most botanical drugs are complex mixtures and may lack a distinct active ingredient. For these reasons, the agency historically paid little heed to or generally neglected any form of herbal medicine.1

 

© 2022 Regulatory Affairs Professionals Society.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe